Celldex Therapeutics' proposed acquisition of CuraGen Corporation will expand Celldex's Precision Targeted Immunotherapy Platform with the addition of a robust portfolio of 11 oncology-focused antibodies. The proposed acquisition will also further strengthen Celldex's intellectual property estate, its balance sheet and support the potential development of additional value-creating milestones and partnering opportunities.

Forward Looking Statements and Participants in the Solicitation
This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are subject to risks and uncertainties that may cause actual future experience and results to differ materially from those discussed in these forward-looking statements.

This communication may be deemed to be solicitation material in respect of the proposed transaction between Celldex and CuraGen. The directors and executive officers of Celldex and CuraGen may be deemed to be participants in the solicitation of proxies from the holders of Celldex and CuraGen common stock in respect of the proposed transaction. In connection with the proposed transaction, Celldex and CuraGen intend to file relevant materials with the SEC, including a joint proxy statement/prospectus. INVESTORS ARE URGED TO READ THESE MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION.